During the past decade, Warren Paroly, MD conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Warren Paroly, MD" are "Carcinoma, Non-Small Cell Lung" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Lung Cancer" (1 trials), "Neoplasms, Lung" (1 trials) and "Neoplasms, Pulmonary" (1 trials). Many other conditions were trialed in "Warren Paroly, MD" in a lesser frequency.

Most popular intervention types in "Warren Paroly, MD" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "docetaxel" (1 trials), "pemetrexed" (1 trials), "talabostat" (1 trials) and "talabostat mesylate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Warren Paroly, MD" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Warren Paroly, MD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Warren Paroly, MD, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Warren Paroly, MD, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".